Advances in the Investigation of the Oncological Functions and its Target Therapy of Interleukin-1 Receptor-associated Kinase 1 (IRAK1)
Keywords:
Interleukin-1 receptor-associated kinase 1 (IRAK1), Tumor progression, Tumor immunity, IRAK1 inhibitorsAbstract
Interleukin-1 receptor-associated kinase 1 (IRAK1) plays as a pivotal regulator within the innate immune signaling and inflammatory processes. Being a critical component in many signaling pathways, emerging evidence strongly suggests the involvement of IRAK1 in the pathophysiology of cancers, thereby rendering it an attractive target for therapeutic intervention. Notably, selective IRAK1-inhibitory molecules have been identified, opening promising avenues for the therapy of tumor. In this review, we also delve into the challenges and future prospects in this field, emphasizing the importance of gaining a deeper understanding of IRAK1 regulation in tumors and the potential of combination therapies targeting IRAK1.
References
Corrales L, Matson V, Flood B, et al., 2017, Innate Immune Signaling and Regulation in Cancer Immunotherapy. Cell Research, 27(1): 96–108.
Janssens S, Beyaert R, 2003, Functional Diversity and Regulation of Different Interleukin-1 Receptor-Associated Kinase (IRAK) Family Members. Molecular Cell, 11(2): 293–302.
Knop J, Martin MU, 1999, Effects of IL-1 Receptor-Associated Kinase (IRAK) Expression on IL-1 Signaling Are Independent of Its Kinase Activity. FEBS Letters, 448(1): 81–85.
Lye E, Mirtsos C, Suzuki N, et al., 2004, The Role of Interleukin 1 Receptor-Associated Kinase-4 (IRAK-4) Kinase Activity in IRAK-4-Mediated Signaling. Journal of Biological Chemistry, 279(39): 40653–40658.
Sprinzl MF, Galle PR, 2014, Immune Control in Hepatocellular Carcinoma Development and Progression: Role of Stromal Cells. Seminars in Liver Disease, 34(4): 376–388.
Li W, Xiao J, Zhou X, et al., 2015, STK4 Regulates TLR Pathways and Protects Against Chronic Inflammation-Related Hepatocellular Carcinoma. Journal of Clinical Investigation, 125(11): 4239–4254.
Cheng BY, Lau EY, Leung HW, et al., 2018, IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. Cancer Research, 78(9): 2332–2342.
Meng DF, Sun R, Liu GY, et al., 2020, S100A14 Suppresses Metastasis of Nasopharyngeal Carcinoma by Inhibition of NF-κB Signaling Through Degradation of IRAK1. Oncogene, 39(30): 5307–5322.
Liu L, Liu S, Deng P, et al., 2021, Targeting the IRAK1–S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma. Cancer Research, 81(5): 1413–1425.
Li J, Sun Y, Ma Y, et al., 2022, Comprehensive Pan-Cancer Analysis of IRAK Family Genes Identifies IRAK1 as a Novel Oncogene in Low-Grade Glioma. Journal of Oncology, 2022: 6497241.
Hozaka Y, Kita Y, Yasudome R, et al., 2021, RNA-Sequencing Based microRNA Expression Signature of Colorectal Cancer: The Impact of Oncogenic Targets Regulated by miR-490-3p. International Journal of Molecular Sciences, 22(18): 9876.
Feng Z, Duan Z, Shi G, et al., 2021, Pharmacological Inhibition of IRAK1 Attenuates Colitis-Induced Tumorigenesis in Mice by Inhibiting the Inflammatory Response and Epithelial-Mesenchymal Transition. Journal of Biochemical and Molecular Toxicology, 35(9): e22838.
Jin Z, Liang F, Yang J, et al., 2017, hnRNP I Regulates Neonatal Immune Adaptation and Prevents Colitis and Colorectal Cancer. PLoS Genetics, 13(3): e1006672.
Yang M, Qin X, Qin G, et al., 2019, The Role of IRAK1 in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. OncoTargets and Therapy, 12: 2171–2180.
Wee ZN, Yatim SMJM, Kohlbauer VK, et al., 2015, IRAK1 is a Therapeutic Target That Drives Breast Cancer Metastasis and Resistance to Paclitaxel. Nature Communications, 6: 8746.
Liu F, Li L, Lan M, et al., 2021, Psoralen-Loaded Polymeric Lipid Nanoparticles Combined with Paclitaxel for the Treatment of Triple-Negative Breast Cancer. Nanomedicine (London), 16(27): 2411–2430.
Schagdarsurengin U, Breiding V, Loose M, et al., 2022, Interleukin-1 Receptor-Associated Kinase 1 (IRAK1) is Epigenetically Activated in Luminal Epithelial Cells in Prostate Cancer. Frontiers in Oncology, 12: 991368.
Shareef ZA, Hachim MY, Talaat IM, et al., 2023, DKK3’s Protective Role in Prostate Cancer is Partly Due to the Modulation of Immune-Related Pathways. Frontiers in Immunology, 14: 978236.
Behrens C, Feng L, Kadara H, et al., 2010, Expression of Interleukin-1 Receptor-Associated Kinase-1 in Non-Small Cell Lung Carcinoma and Preneoplastic Lesions. Clinical Cancer Research, 16(1): 34–44.
Liu YN, Tsai MF, Wu SG, et al., 2020, miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway. Molecular Therapy Nucleic Acids, 22: 471–483.
Yan Z, Wen JX, Cao XS, et al., 2022, Tumor Cell-Derived Exosomal MicroRNA-146a Promotes Non-Small Cell Lung Cancer Cell Invasion and Proliferation by Inhibiting M1 Macrophage Polarization. Annals of Translational Medicine, 10(24): 1307.
Wang Y, Wang Y, Duan X, et al., 2018, Interleukin-1 Receptor-Associated Kinase 1 Correlates with Metastasis and Invasion in Endometrial Carcinoma. Journal of Cell Biochemistry, 119(3): 2545–2555.
Wang Y, Hu M, Yang L, et al., 2022, miR-192-5p-Modified Tumor-Associated Macrophages-Derived Exosome Suppressed Endometrial Cancer Progression Through Targeting IRAK1/NF-κB Signaling. Reproduction Science, 29(2): 436–447.
Flemming JP, Hill BL, Haque MW, et al., 2020, miRNA- and Cytokine-Associated Extracellular Vesicles Mediate Squamous Cell Carcinomas. Journal of Extracellular Vesicles, 9(1): 1790159.
Hung PS, Liu CJ, Chou CS, et al., 2013, miR-146a Enhances the Oncogenicity of Oral Carcinoma by Concomitant Targeting of the IRAK1, TRAF6, and NUMB Genes. PLoS One, 8(11): e79926.
Adams AK, Bolanos LC, Dexheimer PJ, et al., 2015, IRAK1 Is a Novel DEK Transcriptional Target and Is Essential for Head and Neck Cancer Cell Survival. Oncotarget, 6(41): 43395–43407.
Khan H, Pandey SN, Mishra A, et al., 2022, Suppression of TLR Signaling by IRAK-1 and -4 Dual Inhibitor Decreases TPF-Resistance-Induced Pro-Oncogenic Effects in HNSCC. 3 Biotech, 13(1): 14.
Srivastava R, Geng D, Liu Y, et al., 2012, Augmentation of Therapeutic Responses in Melanoma by Inhibition of IRAK-1,-4. Cancer Research, 72(23): 6209–6216.
Sogutlu F, Kayabasi C, Yelken BO, et al., 2021, The Evaluation of Effect of Aurora Kinase Inhibitor CCT137690 in Melanoma and Melanoma Cancer Stem Cell. Anticancer Agents Med Chem, 21(12): 1564–1574.
Fu L, Zhang J, Shen B, et al., 2021, Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL. Journal of Medicine Chemistry, 64(15): 10878–10889.
Cai B, Liu Y, Chong Y, et al., 2021, IRAK1-Regulated IFN-γ Signaling Induces MDSC to Facilitate Immune Evasion in FGFR1-Driven Hematological Malignancies. Mol Cancer, 20: 165.
Hosseini MM, Kurtz SE, Abdelhamed S, et al., 2018, Inhibition of Interleukin-1 Receptor-Associated Kinase-1 Is a Therapeutic Strategy for Acute Myeloid Leukemia Subtypes. Leukemia, 32(11): 2374–2387.
Melgar K, Walker MM, Jones LM, et al., 2019, Overcoming Adaptive Therapy Resistance in AML by Targeting Immune Response Pathways. Science Translation Medicine, 11(508): eaaw8828.
Li Z, Younger K, Gartenhaus R, et al., 2015, Inhibition of IRAK1/4 Sensitizes T Cell Acute Lymphoblastic Leukemia to Chemotherapies. Journal of Clinical Investigation, 125(3): 1081–1097.
Lin C, Chen D, Xiao T, et al., 2021, DNA Methylation‐Mediated Silencing of microRNA‐204 Enhances T Cell Acute Lymphoblastic Leukemia by Up‐Regulating MMP‐2 and MMP‐9 via NF‐kB. Journal of Cell Molecular Medicine, 25(5): 2365–2376.
Liang K, Volk AG, Haug JS, et al., 2017, Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia. Cell, 168(1–2): 59–72.
Yang G, Zhou Y, Liu X, et al., 2013, A Mutation in MYD88 (L265P) Supports the Survival of Lymphoplasmacytic Cells by Activation of Bruton Tyrosine Kinase in Waldenström Macroglobulinemia. Blood, 122(7): 1222–1232.
Kawamura Y, Saijo K, Imai H, et al., 2021, Inhibition of IRAK1/4 Enhances the Antitumor Effect of Lenvatinib in Anaplastic Thyroid Cancer Cells. Cancer Science, 112(11): 4711–4721.
Wu X, Wang L, Qiu Y, et al., 2017, Cooperation of IRAK1/4 Inhibitor and ABT-737 in Nanoparticles for Synergistic Therapy of T Cell Acute Lymphoblastic Leukemia. International Journal of Nanomedicine, 12: 8025–8034.
Rahemi S, Nematollahi-Mahani SN, Rajaie A, et al., 2019, Inhibitor of Interleukin-1 Receptor-Associated Kinases 1/4 Can Increase the Sensitivity of Breast Cancer Cells to Methotrexate. International Journal of Molecular and Cellular Medicine, 8(3): 200–209.
Rhyasen GW, Bolanos L, Fang J, et al., 2013, Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome. Cancer Cell, 24(1): 90–104.
Hatcher JM, Yang G, Wang L, et al., 2020, Discovery of a Selective, Covalent IRAK1 Inhibitor With Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma. ACS Medicinal Chemistry Letters Journal, 11(11): 2238–2243.
Pan B, Gao J, Chen W, et al., 2020, Selective Inhibition of Interleukin-1 Receptor-Associated Kinase 1 Ameliorates Lipopolysaccharide-Induced Sepsis in Mice. International Immunopharmacology, 85: 106597.
Liu M, Que Y, Hong Y, et al., 2022, A Pan-Cancer Analysis of IRAK1 Expression and Their Association With Immunotherapy Response. Frontiers of Molecular Bioscience, 9: 904959.
Scarneo SA, Hughes PF, Yang KW, et al., 2020, A Highly Selective Inhibitor of Interleukin-1 Receptor–Associated Kinases 1/4 (IRAK-1/4) Delineates the Distinct Signaling Roles of IRAK-1/4 and the TAK1 Kinase. Journal of Biological Chemistry, 295(6): 1565–1574.
Totzke J, Gurbani D, Raphemot R, et al., 2017, Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease. Cell Chemistry and Biology, 24(8): 1029–1039.
